0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Secondary Hyperparathyroidism - Epidemiology Forecast to 2028
Published Date: April 2019
|
Report Code: DELV-Epid-238
Home | Market Reports | Health | Health Conditions
Secondary Hyperparathyroidism Epidemiology Forecast to 2028

Secondary Hyperparathyroidism - Epidemiology Forecast to 2028

Code: DELV-Epid-238
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Secondary Hyperparathyroidism - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Secondary Hyperparathyroidism epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Secondary Hyperparathyroidism Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Secondary Hyperparathyroidism in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Secondary Hyperparathyroidism outlook. It also includes the explanation of changing trends of epidemiology outlining the Secondary Hyperparathyroidism scenario.

Secondary Hyperparathyroidism Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Secondary Hyperparathyroidism thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Secondary Hyperparathyroidism explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Secondary Hyperparathyroidism Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Secondary Hyperparathyroidism

Key assessments
• Patient Segmentation in Secondary Hyperparathyroidism
• Secondary Hyperparathyroidism Risk & Burden
• Factors driving growth in a specific Secondary Hyperparathyroidism patient population

1. Report Introduction
2. Secondary Hyperparathyroidism Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Secondary Hyperparathyroidism in 2016
2.2. Patient Share Distribution of Secondary Hyperparathyroidism in 2028
3. Disease Background and Overview: Secondary Hyperparathyroidism
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Secondary Hyperparathyroidism in 7MM
4.3. Total Prevalent/ Incident Patient Population of Secondary Hyperparathyroidism in 7MM – By Countries
5. Epidemiology of Secondary Hyperparathyroidism by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.1.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.1.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.1.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.4.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.4.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.4.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.5.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.5.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.5.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.6.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.6.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.6.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.7.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.7.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.7.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.8.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.8.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.8.5. Diagnosed Cases of the Secondary Hyperparathyroidism
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Secondary Hyperparathyroidism
5.9.3. Sub-Type Specific cases of the Secondary Hyperparathyroidism *
5.9.4. Sex- Specific Cases of the Secondary Hyperparathyroidism *
5.9.5. Diagnosed Cases of the Secondary Hyperparathyroidism
6. Unmet Needs of the Secondary Hyperparathyroidism
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Secondary Hyperparathyroidism in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Hyperparathyroidism in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Secondary Hyperparathyroidism in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Secondary Hyperparathyroidism in United States (2016-2028)*
Table 6: Diagnosed Cases of the Secondary Hyperparathyroidism in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Secondary Hyperparathyroidism in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Secondary Hyperparathyroidism in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in France (2016-2028)
Table 12: Sub-Type Specific cases of the Secondary Hyperparathyroidism in France (2016-2028) *
Table 13: Sex- Specific Cases of the Secondary Hyperparathyroidism in France (2016-2028) *
Table 14: Diagnosed Cases of the Secondary Hyperparathyroidism in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Secondary Hyperparathyroidism in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Secondary Hyperparathyroidism in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Secondary Hyperparathyroidism in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Secondary Hyperparathyroidism in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Secondary Hyperparathyroidism in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Secondary Hyperparathyroidism in UK (2016-2028) *
Table 26: Diagnosed Cases of the Secondary Hyperparathyroidism in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Secondary Hyperparathyroidism in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Secondary Hyperparathyroidism in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Secondary Hyperparathyroidism in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Hyperparathyroidism in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Secondary Hyperparathyroidism in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Secondary Hyperparathyroidism in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Secondary Hyperparathyroidism in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Secondary Hyperparathyroidism in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Secondary Hyperparathyroidism in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Secondary Hyperparathyroidism in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Secondary Hyperparathyroidism in France (2016-2028) *
Figure 14: Diagnosed Cases of the Secondary Hyperparathyroidism in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Secondary Hyperparathyroidism in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Secondary Hyperparathyroidism in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Secondary Hyperparathyroidism in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Secondary Hyperparathyroidism in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Secondary Hyperparathyroidism in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Secondary Hyperparathyroidism in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Secondary Hyperparathyroidism in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Secondary Hyperparathyroidism in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Secondary Hyperparathyroidism in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Secondary Hyperparathyroidism in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Secondary Hyperparathyroidism in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Accenture

RELATED REPORTS

Global Infectious Disease Diagnosis Market Size Status and Forecast 2021 2027
Global Infectious Disease Diagnosis Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10N1843
Sun Jul 18 00:00:00 UTC 2021

Add to Cart

Global Glottic Cancer Treatment Market Size Status and Forecast 2021 2027
Global Glottic Cancer Treatment Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-25Y923
Sun Jul 18 00:00:00 UTC 2021

Add to Cart

Global Inflammatory Bowel Disease Market Size Status and Forecast 2021 2027
Global Inflammatory Bowel Disease Market Size, Status and Forecast 2021-2027

The global Inflammatory Bowel Disease market size is projected to reach US 16820 million by 2027 from US 12800 million in 2020 at a CAGR of 3.5 during 20212027.Global Inflammatory Bowel Disease Market Size Status and Forecast 20212027.

120 Pages
Type: Report
Code: QYRE-Auto-39W5849
Sun Jul 18 00:00:00 UTC 2021

Add to Cart

Global Oral Cancer Diagnosis Market Size Status and Forecast 2021 2027
Global Oral Cancer Diagnosis Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-3X3195
Sun Jul 18 00:00:00 UTC 2021

Add to Cart